Compare Caesars Entertainment Inc (CZR) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Caesars Entertainment Inc vs Cassava Sciences Inc — how do they compare? Caesars Entertainment Inc trades at $29.5 (market cap $6.02B), while Cassava Sciences Inc trades at $0.82 (market cap $39.40M). The key difference: Caesars Entertainment Inc is far larger — about 152.8× Cassava Sciences Inc's market cap, and Caesars Entertainment Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Caesars Entertainment Inc for 31 Days and Cassava Sciences Inc for 37 Days on average.
| CZR | FLNA | |
|---|---|---|
Market Cap | $6.02B | $39.40M |
Volume | 6,412,151 | 759,018 |
Sector | Consumer Cyclical | Health |
52-Week High | $30.41 | $4.64 |
52-Week Low | $18.14 | $0.68 |
Typical Hold Time | 31 Days | 37 Days |
Enterprise Value | $29.91B | -$43.28M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CZR trades at $29.52, up 0.1% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $502 million in 2025, with negative profit margins and consecutive earnings misses. A pending merger with Fertitta Entertainment at $31 per share is under regulatory review, while analyst consensus is mixed with a $30.75 price target.
The outlook is cautious due to persistent losses and high debt, though cash flow from operations remains positive. Risks include merger uncertainty and competitive pressures, but the stock trades below some valuation metrics, offering potential upside if profitability improves post-merger.
FLNA trades at $0.8136, down 0.26% today, with a bearish technical signal from moving averages but neutral oscillators. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates in recent quarters. Recent positive news includes FDA lifting a clinical hold on its epilepsy drug, enabling Phase 2a studies.
The outlook remains high-risk due to persistent negative cash flows and lack of revenue, but analyst consensus is bullish with 67% buy ratings. Key risks include clinical trial execution and funding needs, while the FDA decision provides a potential catalyst for long-term investors focused on biotech turnaround stories.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Caesars Entertainment Inc
Caesars Entertainment includes around 50 domestic gaming properties across Las Vegas (50% of 2021 EBITDAR before corporate and digital expenses) and regional (63%) markets. Additionally, the company hosts managed properties and digital assets, the later of which produced material EBITDA losses in 2021. Caesars' U.S. presence roughly doubled with the 2020 acquisition by Eldorado, which built its first casino in Reno, Nevada, in 1973 and expanded its presence through prior acquisitions to over 20 properties before merging with legacy Caesars. Caesars' brands include Caesars, Harrah's, Tropicana, Bally's, Isle, and Flamingo. Also, the company owns the U.S. portion of William Hill (it plans to sell the international operation in 2022), a digital sports betting platform.
Read more on CZR →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
